Amgen eyeing $20 billion acquisition
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
<strong>Amgen defies the bear market</strong>
Thousand Oaks biotech giant posts solid results By Jorge Mercado Senior Staff Writer Thousand Oaks-based Amgen’s shares have soared to record highs, even as competitors’ stocks have been hammered by the bull market. Amgen, one of the world’s largest biotechnology companies, has been up about 25% year to date, compared to a loss of 29% Read More →
<strong>In search of a new strategy</strong>
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind reports loss but record revenue for Q3
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara shares drop after larger Q3 loss than expected
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arcutis reports Q3 loss, but first product revenue
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
